Ohio Life Insurance - Save up to 70% Off
See what plans you qualify for in just a few minutes
How Life Insurance Underwriters View GLP-1 Medications
GLP-1 receptor agonists, including Ozempic, Wegovy, Mounjaro, and Zepbound, are now among the most commonly prescribed medications in the United States. By March 2026, nearly 8% of all prescriptions were for GLP-1 receptor agonists, and underwriters are encountering these drugs on applications daily. Their approach has evolved significantly from just a few years ago.
The good news: taking a GLP-1 medication does not automatically disqualify you from life insurance, and in many cases, it may actually work in your favor. Underwriters are increasingly outcome-focused. They care far less about the drug name itself and far more about your underlying health trajectory: whether your weight is dropping, your blood sugar is controlled, your blood pressure is improving, and whether obesity-related conditions are resolving.
Here's how most insurers approach GLP-1 use today:
| Applicant Profile | Likely Underwriting Outcome |
|---|---|
| Well-controlled diabetes, improved A1c, no complications | Standard or near-standard rates |
| Obesity with 12+ months of documented, stable weight loss | Standard to mildly table-rated |
| Recent GLP-1 start (under 6 months), no track record | Possible postponement, re-apply in 6-12 months |
| High BMI with uncontrolled comorbidities | Table-rated or possible decline |
| Improved labs, resolved conditions (e.g., off CPAP) | Favorable, Preferred possible at progressive carriers |
Many underwriters are now adding approximately half of recent weight loss back into their risk calculations, which is becoming standard across the industry. This "half-credit" rule means that if you lost 40 pounds in the last year on Wegovy, the underwriter may price you closer to a 20-pound loss until stability is proven. Carrier selection matters enormously, because the most progressive insurers now explicitly allow Preferred rate classes for applicants whose GLP-1 use has produced documented, sustained health improvements.
If you're managing multiple health factors, it's also worth reading our guide on life insurance with pre-existing conditions to understand how insurers layer multiple risks together.
Ohio Life Insurance - Save up to 70% Off
See what plans you qualify for in just a few minutes
GLP-1 for Diabetes vs. Weight Loss: Key Underwriting Differences
The single biggest underwriting distinction for GLP-1 users is why the medication was prescribed. Insurers treat these two use cases quite differently.
If Your GLP-1 Is for Type 2 Diabetes (Ozempic, Mounjaro)
Underwriters focus heavily on your A1c level, the duration of your diagnosis, and the presence of any complications. A well-managed diabetic with a stable A1c under 7% and no neuropathy, retinopathy, or kidney disease can often qualify for Standard rates or close to it. Even brief interruptions in GLP-1 therapy can elevate the risks of heart attack, stroke, and mortality among individuals with Type 2 diabetes, so underwriters view consistent, uninterrupted use as a strong positive signal.
For a deeper look at how diabetes specifically affects your application, see our guide on life insurance for diabetics.
If Your GLP-1 Is for Weight Loss / Obesity (Wegovy, Zepbound)
For weight-loss use, the underwriter's primary question is: Has the risk actually improved and is it stable? Because of uncertainty around long-term maintenance after GLP-1-induced weight loss, many carriers apply a "12-month stability rule," postponing a case until weight has been stable for at least 12 months. They want to see documented weight loss over that window, improvement in obesity-related conditions like high blood pressure or sleep apnea, and consistent, regular medication fills.
If obesity is part of your profile, our dedicated guide on life insurance with obesity walks through exactly how BMI and build charts affect your rate class.
The Mortality Data That's Changing the Insurance Industry
Perhaps the most significant reason insurers are warming to GLP-1 users is the rapidly accumulating evidence that these drugs materially reduce mortality risk. Two major reinsurers, Munich Re and Swiss Re, have both published analyses that are reshaping how the industry thinks about these medications.
What the Data Shows
Munich Re analyzed a de-identified U.S. dataset covering 41 million adults from 2015 through January 2025, examining deaths observed between 2023 and 2025. Their headline finding: GLP-1 adoption is linked to a 0.2% to 0.5% annual mortality improvement, realized over roughly 20 years. The mortality benefit was consistent in both diabetic and non-diabetic users, and particularly pronounced in applicants under age 60, which is precisely the demographic that drives the most life insurance business.
Swiss Re's forward-looking model projects that widespread adoption of GLP-1 drugs could reduce cumulative U.S. all-cause mortality by up to 6.4% by 2045, and UK mortality by 1.8% to 5.1%, by improving underlying risk factors like weight, blood sugar, and blood pressure.
Beyond broad mortality gains, recent 2026 meta-analyses have confirmed powerful cardiovascular benefits. A 2026 systematic review found conclusive, high-certainty evidence that GLP-1 receptor agonists reduced all-cause death by 12%, cardiovascular death by 13%, and major adverse cardiovascular events by 13% compared with controls. Additional 2026 research has also found meaningful reductions in substance use disorders and overdose events among GLP-1 users, though that evidence is still emerging.
Additionally, in January 2026, the FDA requested that pharmaceutical companies eliminate warnings regarding potential suicidal thoughts associated with popular GLP-1 weight-loss medications, including Wegovy, Zepbound, and Saxenda, after review found no evidence linking these drugs to suicidal ideation. This removed a prior concern that some underwriters had flagged.
This data is shifting insurer attitudes from caution to cautious optimism. If insurers fail to account for GLP-1 improvements in their underwriting, they risk overestimating mortality risk for these applicants, which leads to overpriced coverage and adverse selection as healthier GLP-1 users shop elsewhere.
If you have other conditions that may interact with your application, such as high blood pressure, those are increasingly being viewed through the lens of whether a GLP-1 has helped bring them under control.
How to Disclose GLP-1 Use on a Life Insurance Application
Proper disclosure is non-negotiable. Failing to disclose a GLP-1 on your application is a material misrepresentation that can void the policy during the two-year contestability period, and the carrier does not need to prove intent to deceive. Here's how to handle it correctly.
What You Must Disclose
GLP-1 medications should be disclosed anywhere the application asks about:
- Current prescription medications (list drug name, dose, frequency, and start date)
- Diabetes, prediabetes, or elevated blood sugar
- Obesity, weight loss treatment, or weight loss injections
- Cardiovascular risk factors or heart disease
- Related conditions such as high blood pressure, sleep apnea, or high cholesterol
Note that insurers now have significantly better detection tools. Prescription database checks, pharmacy records, and physician statements make non-disclosure both detectable and legally risky. This applies even for no medical exam life insurance policies, which rely on self-reported data but still cross-reference pharmacy and EHR records.
How to Frame Your Disclosure
A strong, clear medication disclosure looks like this:
"Semaglutide (Ozempic) 1 mg weekly for Type 2 diabetes diagnosed 2022. A1c 6.4% as of March 2026, no complications. Weight stable."
"Tirzepatide (Zepbound) 10 mg weekly for obesity (BMI 37 to 31) with hypertension and sleep apnea, started June 2025. Lost 45 lbs. Blood pressure improved to 122/78."
If the application has a free-text section, use it to highlight positive trends: weight loss trajectory, resolved conditions, reduced medications, and clinical stability.
What Underwriters Will Ask About
Applications now include detailed queries about exact weight loss amounts in specific timeframes, use of prescription weight loss medications, and methods used for weight loss. Expect follow-up questions (directly or via your physician's records) covering:
Being transparent, consistent, and well-documented gives underwriters the information they need to justify a favorable rate class. Inconsistencies between your application and your medical records are a red flag, and carriers now routinely cross-reference pharmacy databases and attending physician statements.
Since GLP-1 use often occurs alongside other manageable health conditions, it's worth reviewing how pre-existing conditions are handled during the underwriting process.
Frequently Asked Questions
Will taking Ozempic or Wegovy automatically raise my life insurance rates?
No, GLP-1 medications do not automatically increase your premiums. In 2026, most life insurers view these drugs as a neutral to positive factor, depending on your health trajectory. If your weight is down and stable for at least 12 months, your labs have improved, and you have a documented track record on the medication, many carriers will rate you the same as, or better than, a similar applicant not being treated for obesity or diabetes.
Can I qualify for Preferred rates if I take a GLP-1 medication?
Yes, at progressive carriers. If you have documented weight loss sustained for 12+ months, controlled blood sugar or blood pressure, and no significant complications, some insurers will place GLP-1 users in Preferred rate classes. The key is demonstrating sustained improvement with objective clinical data. Working with an independent broker who knows which carriers are most favorable to GLP-1 users is the fastest path to a Preferred offer.
What if I take a GLP-1 medication for diabetes, does that make it harder to get life insurance?
Not necessarily. Taking a GLP-1 for Type 2 diabetes is now treated by most underwriters as evidence of active, responsible disease management. Insurers focus primarily on your A1c level, how long you've been diagnosed, and whether you have complications. A well-controlled diabetic on a GLP-1 with a good A1c and no organ damage can often qualify for Standard rates. Learn more in our guide on life insurance for diabetics.
What happens if I stop taking my GLP-1 medication after I've been approved?
Your approved rate is locked in once your policy is issued, so stopping your medication after approval generally does not affect your premium. However, if you apply for a new policy or increase your coverage later, underwriters will evaluate your current health status at that time. If you've regained weight or your health metrics have worsened since stopping, it could affect your new application. Recent research also suggests interrupting GLP-1 therapy can raise cardiovascular risk, so any decision to stop should be made with your physician.
Do I have to disclose my GLP-1 medication if I'm buying a no-medical-exam life insurance policy?
Yes. Even simplified-issue or no-medical-exam policies require honest disclosure on the application. These policies rely on self-reported health information combined with pharmacy database and EHR checks, and omitting a prescription medication is considered misrepresentation. If a claim is filed and the insurer discovers the omission during the contestability period (typically the first two years), they may deny the claim or rescind the coverage. Always disclose fully, regardless of policy type. For more, see our life insurance comparison guide.